Recent findings suggested that eIF4E is a key determinant of PI3K/Akt/mTOR- and Ras/Raf/MAPK-mediated tumorigenic activity, and that targeting eIF4E should have a major impact on these pathways in human cancers [29]. The gene discussed is EIF4E; the disease is cancer.